2022
Uncovering the molecular identity of cardiosphere-derived cells (CDCs) by single-cell RNA sequencing
Kogan P, Wirth F, Tomar A, Darr J, Teperino R, Lahm H, Dreßen M, Puluca N, Zhang Z, Neb I, Beck N, Luzius T, de la Osa de la Rosa L, Gärtner K, Hüls C, Zeidler R, Ramanujam D, Engelhardt S, Wenk C, Holdt L, Mononen M, Sahara M, Cleuziou J, Hörer J, Lange R, Krane M, Doppler S. Uncovering the molecular identity of cardiosphere-derived cells (CDCs) by single-cell RNA sequencing. Basic Research In Cardiology 2022, 117: 11. PMID: 35258704, PMCID: PMC8902493, DOI: 10.1007/s00395-022-00913-y.Peer-Reviewed Original ResearchConceptsSingle-cell RNA sequencingExtracellular vesiclesRNA sequencingMolecular identityCell typesMitochondria-rich cell typesCardiosphere-derived cellsMitochondria-rich cellsHuman-induced pluripotent stem cellsPluripotent stem cellsCardiac progenitor cellsPro-apoptotic BaxGO termsNon-hematopoietic cellsCardiac developmentTranscriptomic similarityStem cellsProgenitor cellsCellular originNon-myocyte cellsNew specific markerCulture conditionsBiological similaritiesSpecial culture conditionsSequencing
2015
Programming and reprogramming a human heart cell
Sahara M, Santoro F, Chien K. Programming and reprogramming a human heart cell. The EMBO Journal 2015, 34: 710-738. PMID: 25712211, PMCID: PMC4369310, DOI: 10.15252/embj.201490563.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsStem cell biologyCardiac regenerative therapeuticsHuman heart cellsCardiac regenerative medicineHuman cardiogenesisMolecular programsCell biologyRegenerative therapeuticsCardiac regenerationHeart cellsRegenerative medicineDevelopmental cardiologyLatest discoveriesNovel therapeutic toolDiseased heartCardiac muscleCellsCardiogenesisTherapeutic strategiesClinical practiceTherapeutic toolBiologyModest outcomesCurrent controversiesDeeper understanding
2013
Driving vascular endothelial cell fate of human multipotent Isl1+ heart progenitors with VEGF modified mRNA
Lui K, Zangi L, Silva E, Bu L, Sahara M, Li R, Mooney D, Chien K. Driving vascular endothelial cell fate of human multipotent Isl1+ heart progenitors with VEGF modified mRNA. Cell Research 2013, 23: 1172-1186. PMID: 24018375, PMCID: PMC3790234, DOI: 10.1038/cr.2013.112.Peer-Reviewed Original ResearchConceptsEndothelial specificationHeart progenitorsEndothelial cell fateCell fate decisionsCell fate switchHuman embryonic stem cellsCell-specific genesStem cellsEmbryonic stem cellsHuman pluripotent stem cellsEndothelial cell lineagesPluripotent stem cellsLarge-scale derivationCell fateMammalian cardiogenesisCardiovascular progenitorsMultipotent progenitorsHuman ESCsRegenerative therapeutic potentialCell lineagesEfficient expressionDistinct familiesAngiocrine factorsIsl1Endothelial intermediate
2010
A Phosphodiesterase-5 Inhibitor Vardenafil Enhances Angiogenesis Through a Protein Kinase G-Dependent Hypoxia-Inducible Factor-1/Vascular Endothelial Growth Factor Pathway
Sahara M, Sata M, Morita T, Nakajima T, Hirata Y, Nagai R. A Phosphodiesterase-5 Inhibitor Vardenafil Enhances Angiogenesis Through a Protein Kinase G-Dependent Hypoxia-Inducible Factor-1/Vascular Endothelial Growth Factor Pathway. Arteriosclerosis Thrombosis And Vascular Biology 2010, 30: 1315-1324. PMID: 20413734, DOI: 10.1161/atvbaha.109.201327.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis Inducing AgentsAnimalsCapillariesCell HypoxiaCell MovementCells, CulturedCollateral CirculationCyclic GMPCyclic GMP-Dependent Protein KinasesCyclic Nucleotide Phosphodiesterases, Type 5Disease Models, AnimalEndothelial CellsGreen Fluorescent ProteinsHindlimbHumansHypoxia-Inducible Factor 1, alpha SubunitImidazolesIschemiaMaleMiceMice, Inbred C3HMice, Inbred C57BLMice, KnockoutMice, TransgenicMuscle, SkeletalNeovascularization, PhysiologicNitric Oxide Synthase Type IIIPhosphodiesterase 5 InhibitorsPhosphodiesterase InhibitorsPiperazinesRecovery of FunctionRegional Blood FlowRNA InterferenceSignal TransductionStem CellsSulfonesTime FactorsTransfectionTriazinesVardenafil DihydrochlorideVascular Endothelial Growth Factor AConceptsEndothelial progenitor cellsVascular endothelial growth factor (VEGF) pathwayEndothelial growth factor pathwayIschemia-induced angiogenesisGrowth factor pathwaysIschemic muscleMobilization of EPCsSca-1/flkFactor pathwaySoluble guanylate cyclase inhibitorEndothelial nitric oxide synthasePhosphodiesterase-5 inhibitor vardenafilRight femoral arteryBlood flow recoveryEffect of vardenafilPhosphodiesterase-5 inhibitionUnilateral hindlimb ischemiaGuanylate cyclase inhibitorVascular endothelial growth factorNitric oxide synthaseUpregulated protein expressionProtein kinase G inhibitorIschemic cardiovascular diseaseCapillary-like tube formationEndothelial growth factor
2005
Comparison of Various Bone Marrow Fractions in the Ability to Participate in Vascular Remodeling After Mechanical Injury
Sahara M, Sata M, Matsuzaki Y, Tanaka K, Morita T, Hirata Y, Okano H, Nagai R. Comparison of Various Bone Marrow Fractions in the Ability to Participate in Vascular Remodeling After Mechanical Injury. Stem Cells 2005, 23: 874-878. PMID: 15941860, DOI: 10.1634/stemcells.2005-0012.Peer-Reviewed Original ResearchConceptsHematopoietic stem cellsGreen fluorescent proteinGFP-positive cellsBone marrow cellsTotal bone marrow cellsMarrow cellsFluorescent proteinCell typesBone marrow fractionLin- cellsSca-1Stem cellsVascular cellsMechanical injuryMarrow fractionsCellsHSC cellsBroad potentialBone marrow reconstitutionPluripotencyVascular remodelingLesion formationRecent reportsProteinTransdifferentiation